论文部分内容阅读
目的探讨凋亡抑制因子Bcl-xl在乳腺癌中的表达及与临床病理特征、雌孕激素受体表达的关系。方法用S-P免疫组织化学技术检测39例浸润性乳腺癌组织、35例癌周组织及30例正常、30例增生乳腺组织中凋亡抑制因子Bcl-xl的表达。结果与癌周组织、增生及正常的乳腺组织相比,乳腺癌组织中Bcl-xl呈过表达(P<0.05);乳腺癌组织中Bcl-xl表达随临床分期的升高而升高(P<0.05),随组织分级的增高而升高(P<0.05);乳腺癌组织中Bcl-xl表达和雌激素受体(estrogen receptor,ER)、孕激素受体(progesterone receptor,PR)表达呈负相关(P<0.05);同时也与乳腺癌患者有无腋窝淋巴结转移有关,其在有淋巴结转移组高于无淋巴结转移组(P<0.05)。结论乳腺癌组织中Bcl-xl表达与肿瘤分期,细胞学分级,有无腋窝淋巴结转移,ER、PR表达有相关性,在乳腺癌的发生发展过程中有不可忽视的作用。
Objective To investigate the expression of apoptosis-inhibiting factor Bcl-xl in breast cancer and its relationship with clinicopathological features and estrogen-progesterone receptor expression. Methods S-P immunohistochemistry was used to detect the expression of Bcl-xl in 39 cases of invasive breast cancer, 35 cases of peritumoral tissues and 30 cases of normal and 30 cases of hyperplastic breast tissues. Results Bcl-xl was overexpressed (P <0.05) in breast cancer tissues compared with those in peritumoral tissues, hyperplasia and normal breast tissues. The expression of Bcl-xl in breast cancer tissues increased with the increase of clinical stage (P (P <0.05). The expression of Bcl-xl and the expression of estrogen receptor (ER) and progesterone receptor (PR) in breast cancer tissues were significantly increased (P <0.05), but also with or without axillary lymph node metastasis in patients with breast cancer, which was significantly higher in patients with lymph node metastasis than those without lymph node metastasis (P <0.05). Conclusion The expression of Bcl-xl in breast cancer tissue is correlated with tumor stage, cytological grade, axillary lymph node metastasis, ER and PR expression, which can not be neglected in the occurrence and development of breast cancer.